Gruppo Italiano per lo Studio dell Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase
and heparin versus no heparin among 12,490 patients with acute myocardial
ISIS-2 (Second International Study of Infarct Survival) Collaborative
Group. Randomized trial of intravenous streptokinase, oral aspirin, both,
or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet.1988;2:349-360.
ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic)
Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute
myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet.1999;354:716-722.
GUSTO III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med.1997;337:1118-1123.
Antman E, Guigliano R, Gibson C.
et al. Abciximab facilitates the rate and extent of thrombolysis results of
the thrombolysis in myocaridal infarction (TIMI) 14 trial. Circulation.1999;99:2720-2732.
SPEED Trial Investigators. Randomized trial of abciximab with and without low-dose reteplase for
acute myocardial infarction. Circulation.2000;101:2788-2794.
de Lemos JA, Antman EM, Gibson CM.
et al. Abciximab improves both epicardial flow and myocardial reperfusion
in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation.2000;101:239-243.
GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic
therapy or combination reduced fibrinolytic therapy and platelet glycoprotein
IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet.2001;357:1905-1914.
Lincoff AM, Topol EJ. Illusion of reperfusion: does anyone achieve optimal reperfusion during
acute myocardial infarction? Circulation.1993;87:1792-1805.
[published correction appears in Circulation.
Grines CL, Browne KF, Marco J.
et al. A comparison of immediate angioplasty with thrombolytic therapy for
acute myocardial infarction. N Engl J Med.1993;328:673-679.
GUSTO II Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue
plasminogen activator and recombinant hirudin for acute myocardial infarction. N Engl J Med.1997;336:1621-1628.
Kleiman NS, Ohman EM, Kereiakes DJ.
et al. Profound platelet inactivation with 7E3 shortly after thrombolytic
therapy for acute myocardial infarction: preliminary results of the TAMI 8
Ohman EM, Kleiman NS, Gacioch G.
et al. Combined acclerated tissue-plasminogen activator and platelet glycoprotein
IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction:
results of a randomized, placebo-contolled, dose-ranging trial. Circulation.1997;95:846-854.
PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor
lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation
and reperfusion Gain in Myocardial infarction (PARADIGM) trial. J Am Coll Cardiol.1998;32:2003-2010.
ASSENT-3 (Assessment of Safety and Efficacy of a New Thrombolytic Regimen)
Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin,
abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute
myocardial infarction. Lancet.2001;358:605-613.
Hudson MP, Granger CB, Topol EJ.
et al. Early reinfarction after fibrinolysis: experience from the Global Utilization
of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded
Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded
Coronary Arteries (GUSTO III) trials. Circulation.2001;104:1229-1235.
GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies
for acute myocardial infarction. N Engl J Med.1993;329:673-682.
GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both
on coronary-artery patency, ventricular function, and survival after acute
myocardial infarction. N Engl J Med.1993;329:1615-1622.
Ohman EM, Califf RM, Topol EJ.
et al. Consequences of reocclusion after successful reperfusion therapy in
acute myocardial infarction. Circulation.1990;82:781-791.
White H.for the Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in
patients receiving fibrinolytic therapy for acute myocardial infarction: the
HERO-2 randomised trial. Lancet.2001;358:1855-1863.
Savonitto S, Ardissino D, Lincoff AM.
et al. Age and risk of intracranial haemorrhage with abciximab and half-dose
reteplase in acute MI: dichotomous response in the GUSTO 5 trial [abstract]. Eur Heart J.In press.
Brener SJ, Barr LA, Burchenal JEB.
et al. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa
blockade with primary angioplasty for acute myocardial infarction. Circulation.1998;98:734-741.
Montalescot G, Barragan P, Wittenberg O.
et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for
acute myocardial infarction. N Engl J Med.2001;344:1895-1903.
Neumann F, Kastrati A, Schmitt C.
et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on
clinical and angiographic restenosis rate after the placement of coronary
stents following acute myocardial infarction. J Am Coll Cardiol.2000;35:915-921.